Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern
Koen, A. L.; Izu, A.; Baillie, V.; Kwatra, G.; Cutland, C. L.; Fairlie, L.; Padayachee, S. D.; Dheda, K.; Barnabas, S. L.; Bhorat, Q. E.; Briner, C.; Ahmed, K.; Bhikha, S.; Bhiman, J. N.; du Plessis, J.; Esmail, A.; Horne, E.; Hwa, S.-H.; Oomen-Jose, A.; Lambe, T.; Laubscher, M.; Malahleha, M.; Benade, G.; McKenzie, S.; Oelofse, S.; Patel, F.; Pillay, S.; Rhead, S.; Rodel, H.; Taoushanis, C.; Tegally, H.; Thombrayil, A.; Villafana, T.; Gilbert, S.; Pollard, A. J.; Madhi, S.
Show abstract
In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-type and 77.1% against the Delta variant [≥]9 months after vaccination. VE against infection with the Beta variant, which preceded circulation of Delta, was 6.7%. Clinical trial identifierCT.gov NCT04444674
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine 95%
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 94%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada 94%
Similar papers in this journal
- Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study 96%
- Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting 95%
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France 95%
Similar papers in this journal
Similar papers in this journal
- Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada 97%
- Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States 94%
- SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial 94%
Similar papers in this journal
- COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England 96%
- Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study 95%
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.